Reaction Details |
| Report a problem with these data |
Target | MAP kinase-activated protein kinase 5 |
---|
Ligand | BDBM50026612 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_774403 (CHEMBL1908620) |
---|
Kd | >10000±n/a nM |
---|
Citation | Davis, MI; Hunt, JP; Herrgard, S; Ciceri, P; Wodicka, LM; Pallares, G; Hocker, M; Treiber, DK; Zarrinkar, PP Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol29:1046-51 (2011) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
MAP kinase-activated protein kinase 5 |
---|
Name: | MAP kinase-activated protein kinase 5 |
Synonyms: | MAP kinase-activated protein kinase 5 (PRAK) | MAPK-Activated Protein Kinase 5 (MK5) | MAPK-activated protein kinase 5 | MAPK5_HUMAN | MAPKAP kinase 5 | MAPKAPK5 | PRAK | p38-regulated/activated protein kinase | p38-regulated/activated protein kinase (PRAK) |
Type: | Serine/threonine-protein kinase |
Mol. Mass.: | 54229.92 |
Organism: | Homo sapiens (Human) |
Description: | Recombinant MAPKAPK5 was phosphorylated by incubation with active p38alpha before assays. |
Residue: | 473 |
Sequence: | MSEESDMDKAIKETSILEEYSINWTQKLGAGISGPVRVCVKKSTQERFALKILLDRPKAR
NEVRLHMMCATHPNIVQIIEVFANSVQFPHESSPRARLLIVMEMMEGGELFHRISQHRHF
TEKQASQVTKQIALALRHCHLLNIAHRDLKPENLLFKDNSLDAPVKLCDFGFAKIDQGDL
MTPQFTPYYVAPQVLEAQRRHQKEKSGIIPTSPTPYTYNKSCDLWSLGVIIYVMLCGYPP
FYSKHHSRTIPKDMRRKIMTGSFEFPEEEWSQISEMAKDVVRKLLKVKPEERLTIEGVLD
HPWLNSTEALDNVLPSAQLMMDKAVVAGIQQAHAEQLANMRIQDLKVSLKPLHSVNNPIL
RKRKLLGTKPKDSVYIHDHENGAEDSNVALEKLRDVIAQCILPQAGKGENEDEKLNEVMQ
EAWKYNRECKLLRDTLQSFSWNGRGFTDKVDRLKLAEIVKQVIEEQTTSHESQ
|
|
|
BDBM50026612 |
---|
n/a |
---|
Name | BDBM50026612 |
Synonyms: | BIBF-1120 | Nintedanib | US10981896, Compound Nintedanib | US11046672, Nintedanib | US11208381, Nintedanib | Vargatef |
Type | Small organic molecule |
Emp. Form. | C31H33N5O4 |
Mol. Mass. | 539.6248 |
SMILES | COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1 |
Structure |
|